Acute cardiovascular effects of diltiazem in anesthetized dogs with induced atrial fibrillation.
Atrial fibrillation (AF) is one of the most important arrhythmias of dogs. In a previous study, we determined the dosage of intravenously administered diltiazem necessary to reduce ventricular response (VR), cardiac output (CO), and mean systemic arterial pressure (P(Ao)) to values similar to those observed during sinus rhythm (SR) before induction of AF. The present study was conducted to establish an acute, effective dosage of diltiazem given PO. AF was produced by rapid atrial pacing in healthy, anesthetized Beagle Hounds. Dogs were instrumented to record hemodynamic and electrophysiological parameters. Four dogs were given 2.5 mg/kg diltiazem, and another 4 dogs were given 5 mg/kg diltiazem by stomach tube, whereas 4 other dogs received vehicle in equivalent volumes. Plasma concentrations of diltiazem were measured at various intervals after dosing. A dosage of 5 mg/kg diltiazem produced plasma concentrations of 32-100 ng/mL 3 hours after administration, concentrations within the published effective range for dogs with naturally occurring AF. Between 2 and 3 hours after this dosage, the rate pressure product (RPP) and an index of left ventricular efficiency returned to values similar to those observed during SR. Thus, we believe that diltiazem at anorally administered dosages of 5 mg/kg should be considered to produce therapeutic blood concentrations and favorable hemodynamic effects in dogs with naturally occurring AF. These data must be extrapolated with caution to dogs with long-standing AF produced by natural causes.
Miyamoto
M
M
Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus 43210-1092, USA.
Nishijima
Y
Y
Nakayama
T
T
Hamlin
R L
RL
D000284:Administration, Oral; D000768:Anesthesia, General / Q000662:veterinary; D000818:Animals; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000662:veterinary*; D001794:Blood Pressure; D002317:Cardiovascular Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D004110:Diltiazem / Q000493:pharmacokinetics / Q000494:pharmacology*; D004283:Dog Diseases / Q000188:drug therapy* / Q000503:physiopathology; D004285:Dogs; D004562:Electrocardiography; D005260:Female; D006439:Hemodynamics; D008297:Male
D002317:Cardiovascular Agents; D004110:Diltiazem